Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSPA9 | P38646 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625495 | 0.78 | ALDH1A1 (0.61) | ALDH1A1HSPA9CTSKLMNATSHR | |
| SCHEMBL19405346 | 0.77 | ALDH1A1 (0.59) | ALDH1A1HSPA9CTSKLMNATSHR | |
| SCHEMBL26113007 | 0.77 | ALDH1A1 (0.59) | ALDH1A1HSPA9CTSKLMNATSHR | |
| SCHEMBL8087060 | 0.76 | CTSK (0.50) | MMP2MMP3MMP7CTSKLMNA | |
| SCHEMBL18649650 | 0.75 | ALDH1A1 (0.57) | ALDH1A1HSPA9CTSKRBBP9PLA2G7 | |
| SCHEMBL29469558 | 0.75 | ALDH1A1 (0.57) | ALDH1A1HSPA9CTSKLMNATSHR | |
| SCHEMBL20712728 | 0.74 | HSPA9 (0.60) | ALDH1A1HSPA9CTSKTSHRRBBP9 | |
| SCHEMBL13637584 | 0.73 | ALDH1A1 (0.50) | ALDH1A1HSPA9MMP2MMP3MMP7 | |
| SCHEMBL21814162 | 0.72 | NPC1 (0.48) | ALDH1A1HSPA9LMNATSHRHSPA5 | |
| SCHEMBL4480948 | 0.72 | NPC1 (0.48) | ALDH1A1HSPA9LMNATSHRHSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | ALDH1A1 3887/4885HSPA9 4707/4885MMP2 1319/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885HSPA9 4707/4885MMP2 1319/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885HSPA9 4707/4885MMP2 1319/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | ALDH1A1 3887/4885HSPA9 4707/4885MMP2 1319/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885HSPA9 4707/4885MMP2 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.